Atorvastatin did not prevent cardiovascular events in type 2 diabetes

November 2006
ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p62
Academic Journal
The article presents information on a study that was conducted to examine whether atorvastatin prevents cardiovascular events in diabetic patients. About 2410 diabetic patients were included in the study. The study concluded that in low-risk diabetic patients, atorvastatin did not prevent cardiovascular events.


Related Articles

  • Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus. Athyros, Vasilios G.; Papageorgiou, Athanasios A.; Symeonidis, Athanasios N.; Didangelos, Triandafillos P.; Pehlivanidis, Anthimos N.; Bouloukos, Vasilios I.; Mikhailidis, Dimitrios P. // Angiology;Nov/Dec2003, Vol. 54 Issue 6, p679 

    This is a prospective evaluation of the effect of structured care of dyslipidemia with atorvastatin (strict implementation of guidelines) versus usual care (physician's standard of care) on morbidity and mortality of patients with coronary heart disease (CHD) and diabetes mellitus (DM). From...

  • Primary Prevention of Atrial Fibrillation - The Path Untread. Lardizabal, Joel A.; Deedwania, Prakash C. // JAFIB: Journal of Atrial Fibrillation;Feb/Mar2013, Vol. 5 Issue 5, p131 

    The prevalence and incidence of atrial fibrillation (AF) is on the rapid rise. To slow down the AF epidemic, effective primary prevention strategies need to be instituted. Unfortunately, this is an area that has not been well-explored. There is a multitude of risk factors that predispose to the...

  • BNF underestimates diabetics' CHD risk. Gough, Rob // Pulse;7/7/2003, Vol. 63 Issue 27, p8 

    Reports on the failure of the BNF to accurately estimate the risk of diabetes and coronary heart disease (CHD) in Great Britain. Emphasis on targeting statins to reduce incidence of CHD; Details on the risk criteria for diabetics; Improvements in the treatment of CHD and diabetes.

  • Did AIM-HIGH Start Too Low? Toth, Peter P. // Cardiology Today;Jan2012 Supplement, p10 

    The article discusses the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes trial, which compared the efficacy of statin monotherapy with statin-niacin combination therapy in patients with established coronary artery disease.

  • Statins cut cardiovascular events by a quarter in people with diabetes. Mayor, Susan // BMJ: British Medical Journal (International Edition);6/21/2003, Vol. 326 Issue 7403, p1348 

    Statin treatment reduces major coronary events, revascularisations, and stroke by nearly a quarter in people with diabetes regardless of whether they have occlusive arterial disease or raised cholesterol. The Medical Research Council/British Heart Foundation heart protection study randomly...

  • Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Costa, João; Borges, Margarida; David, Cláudio; Vaz Carneiro, António // BMJ: British Medical Journal (International Edition);5/13/2006, Vol. 332 Issue 7550, p1115 

    Objective To evaluate the clinical benefit of lipid lowering drug treatment in patients with and without diabetes mellitus, for primary and secondary prevention. Design Systematic review and meta-analysis. Data sources Cochrane, Medline, Embase, and reference lists up to April 2004. Study...

  • Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Rotella, Carlo M.; Zaninelli, Augusto; Le Grazie, Cristina; Hanson, Mary E.; Gensini, Gian Franco // Lipids in Health & Disease;2010, Vol. 9, p80 

    Background: Treatment guidelines recommend LDL-C as the primary target of therapy in patients with hypercholesterolemia. Moreover, combination therapies with lipid-lowering drugs that have different mechanisms of action are recommended when it is not possible to attain LDL-C targets with statin...

  • Effect of statins on the clinical outcomes of patients with sepsis. GOODIN, J.; MANRIQUE, C.; DULOHERY, M.; SAMPSON, J.; SAETTELE, M.; DABBAGH, O. // Anaesthesia & Intensive Care;Nov2011, Vol. 39 Issue 6, p1051 

    The article presents a study which aims to examine the impact of statins on the clinical outcomes to patients with sepsis, severe sepsis or septic shock. The study reveals that patients with prior statin use were more obese, older and had higher prevalence of ischaemic heart disease, diabetes...

  • Pravastatin reduced major CHD events in patients with abnormal fasting glucose and a history of CHD. Gami, Apoor S. // ACP Journal Club;Jul/Aug2004, Vol. 141 Issue 1, p5 

    The article presents an overview of secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. In patients with abnormal fasting glucose (diabetes and impaired fasting glucose) and a history of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics